Meeting
2023 ASCO Annual Meeting
Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy.
Authors
Susumu Okano
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Susumu Okano , Makoto Tahara , Yoshinori Imamura , Hideoki Uryu , Tomoyuki Otsuka , Akira Ohkoshi , Daisuke Sano , Kiyoaki Tsukahara , Kazuchika Ono , Toyoyuki Hanazawa , Satoshi Kano , Naoki Nishio , Masato Nagaoka , Naomi Kiyota
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT05694819
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6093)
DOI
10.1200/JCO.2023.41.16_suppl.6093
Abstract #
6093
Poster Bd #
85
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578).
First Author: Laura Locati
Poster
2017 ASCO Annual Meeting
Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303).
First Author: Ken Kato
Poster
2023 ASCO Annual Meeting
177Lu-PSMA radioligand therapy for recurrent/metastatic (R/M) salivary gland cancer (SGC) patients: A phase II pilot study.
First Author: Carla M.L.- Van Herpen
Poster
2022 ASCO Annual Meeting
Overall survival results from a phase II trial of anlotinib plus sintilimab in patients with recurrent advanced cervical cancer.
First Author: Qin Xu